GlobeNewswire: Imunon, Inc. Contains the last 10 of 198 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:46:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853938/0/en/IMUNON-Reports-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=49161IMUNON Reports 2023 Financial Results and Provides Business Update2024-03-28T12:00:00Z<![CDATA[Conference Call Begins Today at 10:00 a.m. Eastern Time]]>https://www.globenewswire.com/news-release/2024/03/25/2851608/0/en/IMUNON-Receives-1-3-Million-from-Sale-of-its-New-Jersey-Net-Operating-Losses.html?f=22&fvtc=4&fvtv=49161IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses2024-03-25T12:30:00Z<![CDATA[Non-dilutive funding strengthens balance sheet and extends current operating runway]]>https://www.globenewswire.com/news-release/2024/03/21/2850655/0/en/IMUNON-to-Hold-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-March-28-2024.html?f=22&fvtc=4&fvtv=49161IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 20242024-03-21T21:00:00Z<![CDATA[LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Thursday, March 28, 2024 to discuss financial results for the year ended December 31, 2023 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.]]>https://www.globenewswire.com/news-release/2024/03/13/2845364/0/en/IMUNON-Files-IND-Application-to-Begin-Human-Testing-of-IMNN-101.html?f=22&fvtc=4&fvtv=49161IMUNON Files IND Application to Begin Human Testing of IMNN-1012024-03-13T12:00:00Z<![CDATA[Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA]]>https://www.globenewswire.com/news-release/2024/03/12/2845063/0/en/IMUNON-Announces-Leadership-Change.html?f=22&fvtc=4&fvtv=49161IMUNON Announces Leadership Change2024-03-12T21:00:00Z<![CDATA[Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.]]>https://www.globenewswire.com/news-release/2024/02/29/2837973/0/en/Independent-Lab-Confirms-Immunogenicity-and-Protection-with-IMUNON-s-IMNN-101-in-a-Live-Virus-Challenge-Against-SARS-CoV-2-Variant-XBB-1-5.html?f=22&fvtc=4&fvtv=49161Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.52024-02-29T13:30:00Z<![CDATA[Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality]]>https://www.globenewswire.com/news-release/2024/02/27/2836041/0/en/Memorial-Sloan-Kettering-Cancer-Center-Now-Enrolling-Patients-in-Phase-1-2-Clinical-Trial-of-IMUNON-s-IMNN-001-in-Combination-with-Bevacizumab-in-Advanced-Ovarian-Cancer.html?f=22&fvtc=4&fvtv=49161Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer2024-02-27T13:30:00Z<![CDATA[Trial will evaluate the effect of this combination therapy on minimal residual disease]]>https://www.globenewswire.com/news-release/2024/02/22/2833646/0/en/IMNN-101-Preclinical-Data-in-SARS-CoV-2-Published-in-Peer-Reviewed-Journal-Vaccine.html?f=22&fvtc=4&fvtv=49161IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine2024-02-22T13:00:00Z<![CDATA[Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality]]>https://www.globenewswire.com/news-release/2023/12/11/2793865/0/en/IMUNON-Appoints-Dr-Sebastien-Hazard-as-Chief-Medical-Officer-and-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=49161IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2023-12-11T13:30:00Z<![CDATA[Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases]]>https://www.globenewswire.com/news-release/2023/11/14/2780144/0/en/IMUNON-s-VP-of-R-D-to-Present-at-the-Vaccines-Summit-2023.html?f=22&fvtc=4&fvtv=49161IMUNON’s VP of R&D to Present at the Vaccines Summit-20232023-11-14T14:00:00Z<![CDATA[Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens]]>